Antibody-Drug Conjugates Are Moving Into Gastrointestinal Oncology’s Center Ring
Gastrointestinal cancers account for a large share of global cancer burden, yet systemic treatment options have remained comparatively limited. In that setting, antibody-drug conjugates have moved from experimental concept to a serious therapeutic strategy, carrying a cytotoxic payload directly to tumor cells through a target-specific antibody and linker system. The promise is straightforward: increase antitumor activity while sparing normal tissue as much as possible. In practice, gastrointestinal tumors have been slower than breast or hematologic malignancies to deliver consistent gains from this approach.
The gap is not due to lack of biological opportunity. Several of the most relevant gastrointestinal targets are already familiar from routine oncology practice, including Claudin 18.2, CEACAM5, and MET. These proteins are attractive because they are expressed across a meaningful fraction of tumors, especially adenocarcinomas, where surface antigen targeting can be exploited to deliver an intracellular toxic payload. The review frames the field as one that has finally begun to generate credible clinical activity after years of lagging behind other tumor types.
Why the Payload Shift Matters in Adenocarcinoma
A central observation in this review is the apparent move from tubulin inhibitor payloads to topoisomerase I inhibitor payloads in newer generations of ADCs. In gastrointestinal cancers, that change appears to matter. The biological rationale is plausible: tumors with high proliferative rates may be especially vulnerable to DNA damage created by topoisomerase I inhibition, and the broader membrane permeability profile of some newer constructs can extend activity beyond the antigen-positive cell itself.
Adenocarcinomas appear to benefit most from this design change.
That pattern is especially visible in the emerging data for MET- and CEACAM5-directed agents, where clinical activity looks stronger than what was typically seen with earlier ADC generations. The review also suggests this effect may extend to other broadly prevalent targets, implying that the payload is no longer a technical detail but a defining feature of clinical performance. For gastroenterologists and oncologists treating refractory disease, the implication is direct: the right target alone may not be enough if the payload does not match the tumor’s biology.
Claudin 18.2, CEACAM5, and MET Define the Current Frontier
The article places Claudin 18.2, CEACAM5, and MET at the forefront of gastrointestinal ADC development. Each target addresses a distinct biological niche, but all share the same therapeutic logic — surface expression that can be used to ferry drug into malignant cells. Their relevance spans multiple gastrointestinal histologies, though the strongest rationale appears to sit within adenocarcinoma-rich disease states.
These targets matter because gastrointestinal cancers are not biologically uniform. Gastric, gastro-oesophageal junction, colorectal, and pancreatic tumors differ in antigen distribution, degree of heterogeneity, and sensitivity to cytotoxic injury. ADCs must therefore solve three problems at once: identify a target, maintain enough target density to achieve binding, and release a payload that remains potent even when antigen expression is uneven across a lesion. The clinical activity already seen with certain agents suggests that this can be done, but the margin for success is narrow.
Heterogeneity remains one of the field’s most difficult obstacles. A single biopsy may not reflect the whole tumor, and prior therapy can alter antigen expression over time. The review points to this issue as a major reason development in gastrointestinal cancers has been delayed relative to other common malignancies. A patient who initially qualifies for a target-driven therapy may later lose that molecular foothold after treatment pressure reshapes the tumor population.
Safety, Resistance, and the Limits of a Targeted Strategy
The appeal of ADCs is often described in elegant terms, but the bedside reality is less forgiving. These drugs still rely on a cytotoxic payload, which means adverse effects remain tied to both target biology and off-target delivery. Toxicity can emerge from the payload itself, from imperfect selectivity, or from the pharmacology of the linker and release process. For gastrointestinal oncology, where patients may already be debilitated by weight loss, obstruction, or prior therapy, tolerability can determine whether an otherwise active drug is usable in routine care.
Resistance is another barrier. Tumors can reduce antigen expression, alter internalization pathways, or adapt to DNA damage and other payload-driven stress. Even when an ADC produces initial shrinkage, durability depends on whether the tumor can maintain the molecular vulnerability that made the treatment work in the first place. In this sense, the challenge is not only to build a better drug but to understand how gastrointestinal tumors rewire themselves under selective pressure.
What the Review Sees as the Next Practical Step
The review is not merely cataloging targets. It is arguing for a more disciplined development strategy in gastrointestinal oncology, one that matches antigen selection, payload choice, and trial design to the biological realities of these tumors. The most compelling signal in the current era comes from newer constructs that use topoisomerase I payloads, especially in adenocarcinoma-heavy settings where earlier ADCs were less persuasive.
Clinical development will likely depend on selecting the right patients, measuring target expression more accurately, and choosing endpoints that reflect meaningful benefit in diseases where survival remains short and treatment lines are limited. Biomarker refinement will be critical because broad target prevalence does not automatically translate into broad response. A target that is common but unevenly expressed can generate disappointing results unless the drug can overcome intratumoral heterogeneity.
The review also points to an important practical reality: progress in gastrointestinal ADCs will not come from one target alone. Success will likely require a portfolio approach, with multiple targets, different payload classes, and better patient selection all moving in parallel. The field now has early signs of activity, but the next step is proving which combinations can deliver durable benefit without sacrificing safety in a population that already has few systemic options.
A Field With Momentum, but Still Several Unanswered Tests
This review captures a moment of momentum rather than a finished therapeutic era. Antibody-drug conjugates have moved closer to meaningful use in gastrointestinal cancers, and the shift toward topoisomerase I payloads may be one reason. Even so, the central questions remain clinical rather than theoretical: which targets truly matter, which payloads deliver the best balance of activity and toxicity, and which patients are most likely to benefit once tumor heterogeneity and prior treatment are taken into account.
The article leaves the field with a clear research agenda. Gastrointestinal oncology now needs better biomarkers, more durable agents, and trials designed to distinguish true biologic signal from transient response. Until those data arrive, ADCs will remain one of the most intriguing strategies in the sector — active enough to matter, but still incomplete enough to demand caution.